Lung cancer, Non small cell lung cancer (NSCLC), Secondary cancers
Results
Phase 3
This trial compared pembrolizumab (MK3475) with chemotherapy for non small cell lung cancer that had spread to another part of the body.
It was for people whose cancer cells had large amounts of a protein called PD-L1 on their surface. This is called PD-L1 positive cancer.
This trial was open for people to join between September 2014 and October 2015. The results were published in 2016 and 2017.
Recruitment start: 3 September 2014
Recruitment end: 2 October 2015
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Christian Ottensmeier
Experimental Cancer Medicine Centre (ECMC)
Merck Sharp & Dohme Ltd
Last reviewed: 24 Sept 2020
CRUK internal database number: 12270
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
